company background image
MRSN logo

Mersana Therapeutics NasdaqGS:MRSN Stock Report

Last Price

US$3.80

Market Cap

US$458.2m

7D

-3.3%

1Y

-37.6%

Updated

19 Feb, 2024

Data

Company Financials +

Mersana Therapeutics, Inc.

NasdaqGS:MRSN Stock Report

Market Cap: US$458.2m

MRSN Stock Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.

MRSN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Mersana Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mersana Therapeutics
Historical stock prices
Current Share PriceUS$3.80
52 Week HighUS$9.62
52 Week LowUS$0.80
Beta1.37
1 Month Change40.22%
3 Month Change140.51%
1 Year Change-37.60%
3 Year Change-80.69%
5 Year Change-46.25%
Change since IPO-72.86%

Recent News & Updates

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Jan 11

Recent updates

Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock

Jan 11

Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Oct 14
Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Jun 09
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Feb 22
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price

Mersana gains as FDA grants fast track status for breast cancer drug

Sep 12

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Aug 15

Taking The Measure Of Mersana Therapeutics

Jan 10

Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress

Jun 29

It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Jun 05
It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year

Mersana Therapeutics EPS misses by $0.11, misses on revenue

May 10

Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Mar 23
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?

Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Jan 29
Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?

Bain Capital discloses 4.8% stake in Mersana Therapeutics

Jan 13

Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst

Jan 11

Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study

Jan 05

Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?

Dec 08
Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?

Mersana Therapeutics EPS misses by $0.02

Nov 09

Shareholder Returns

MRSNUS BiotechsUS Market
7D-3.3%0.6%-0.2%
1Y-37.6%4.4%20.5%

Return vs Industry: MRSN underperformed the US Biotechs industry which returned 4.8% over the past year.

Return vs Market: MRSN underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is MRSN's price volatile compared to industry and market?
MRSN volatility
MRSN Average Weekly Movement14.2%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: MRSN's share price has been volatile over the past 3 months.

Volatility Over Time: MRSN's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2001228Marty Huberhttps://www.mersana.com

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates.

Mersana Therapeutics, Inc. Fundamentals Summary

How do Mersana Therapeutics's earnings and revenue compare to its market cap?
MRSN fundamental statistics
Market capUS$458.21m
Earnings (TTM)-US$197.05m
Revenue (TTM)US$40.84m

11.2x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRSN income statement (TTM)
RevenueUS$40.84m
Cost of RevenueUS$172.48m
Gross Profit-US$131.64m
Other ExpensesUS$65.41m
Earnings-US$197.05m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.63
Gross Margin-322.32%
Net Profit Margin-482.47%
Debt/Equity Ratio48.2%

How did MRSN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.